A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
← catalyst calendarNCT04574076 · readout in 288 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
60estimated
Sites
27
Countries
Austria, Bulgaria, Croatia +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-23 | actual | When the study began enrolling |
| Primary completion | 2027-06-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-03 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haemophilia A
Intervention
- Drug: Turoctocog alfa pegol (N8-GP)
Primary outcome
what the primary-completion date above is the date OFNumber of Adverse Events (AEs) reported during the study period
measured From inclusion of the patient (Visit 1) until the end of study (Visit 3), duration 5-7 years
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed